Spruce Street Capital LP Acquires 75,837 Shares of Dianthus Therapeutics, Inc. $DNTH

Spruce Street Capital LP lifted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 25.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 373,274 shares of the company’s stock after purchasing an additional 75,837 shares during the quarter. Dianthus Therapeutics accounts for approximately 7.6% of Spruce Street Capital LP’s investment portfolio, making the stock its 4th biggest holding. Spruce Street Capital LP’s holdings in Dianthus Therapeutics were worth $31,325,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in Dianthus Therapeutics in the second quarter valued at $27,000. First Horizon Corp bought a new stake in Dianthus Therapeutics during the 1st quarter worth about $32,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Dianthus Therapeutics during the 4th quarter worth about $40,000. Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics during the 3rd quarter worth about $64,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Insider Buying and Selling

In related news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares in the company, valued at approximately $2,424,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the sale, the executive vice president owned 31,249 shares in the company, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 87,779 shares of company stock valued at $7,985,235. 3.02% of the stock is owned by insiders.

Dianthus Therapeutics Stock Performance

Dianthus Therapeutics stock opened at $103.87 on Friday. The stock has a 50-day simple moving average of $90.72 and a 200 day simple moving average of $75.95. The stock has a market capitalization of $5.68 billion, a P/E ratio of -25.15 and a beta of 1.20. Dianthus Therapeutics, Inc. has a 52 week low of $18.08 and a 52 week high of $107.99.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Research analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Raymond James Financial reissued a “strong-buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.82.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.